AU
CA
NZ
UK
US
IND
Kalkine has a fully transformed New Avatar.
Last update at 2025-06-19T02:35:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
18 Stocks Moving in Friday's Pre-Market Session
Fri 08 Oct 21, 11:34 AM| Breakdown | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
| Income before tax | -6.93696M | -3.85504M | -3.11175M | -8.81550M | -3.23543M |
| Minority interest | - | - | - | - | - |
| Net income | -6.93696M | -3.78651M | -2.85425M | -8.38447M | -2.92721M |
| Selling general administrative | 4.52M | 4.22M | 3.52M | 6.09M | 3.12M |
| Selling and marketing expenses | 2.03M | 0.93M | 0.42M | 0.29M | 0.87M |
| Gross profit | 3.34M | 1.31M | 0.52M | 0.09M | 1.83M |
| Reconciled depreciation | 0.05M | 0.05M | 0.04M | 0.04M | 0.04M |
| Ebit | -6.23834M | -3.84540M | -3.10557M | -8.37070M | -3.21380M |
| Ebitda | -6.19236M | -3.79673M | -3.07896M | -8.32704M | -3.16975M |
| Depreciation and amortization | 0.05M | 0.05M | 0.03M | 0.04M | 0.04M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -5.80112M | -6.00040M | -4.05914M | -8.41448M | -3.39058M |
| Other operating expenses | 10.70M | 7.81M | 4.82M | 8.56M | 5.91M |
| Interest expense | 0.00758M | 0.00965M | 0.00618M | 0.01M | 0.02M |
| Tax provision | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Interest income | 0.33M | 0.11M | 0.02M | 0.00920M | 0.02M |
| Net interest income | 0.32M | 0.11M | 0.02M | -0.00456M | -0.02163M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -0.76498M | -0.39288M | -0.25750M | -0.43103M | -0.30823M |
| Total revenue | 4.90M | 1.80M | 0.77M | 0.15M | 2.52M |
| Total operating expenses | 9.14M | 7.31M | 4.58M | 8.51M | 5.22M |
| Cost of revenue | 1.57M | 0.50M | 0.24M | 0.05M | 0.69M |
| Total other income expense net | -1.13584M | -0.28621M | -0.24190M | -0.00456M | -0.32986M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -6.93696M | -3.78651M | -2.85425M | -8.38447M | -2.92721M |
| Net income applicable to common shares | - | -3.78651M | -2.85425M | -8.38447M | -2.92721M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
| Total assets | 15.55M | 21.99M | 24.86M | 27.05M | 6.20M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.10M | 0.16M | 1.03M | 0.08M | 0.03M |
| Total liab | 2.84M | 2.37M | 1.68M | 1.16M | 0.56M |
| Total stockholder equity | 12.71M | 19.62M | 23.18M | 25.90M | 5.64M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 0.56M | 0.29M | 0.03M | 0.02M | 0.04M |
| Common stock | 88.50M | 88.44M | 88.44M | 88.36M | 62.43M |
| Capital stock | - | 88.44M | 88.44M | 88.36M | 62.43M |
| Retained earnings | -78.96840M | -72.05540M | -68.42528M | -65.93289M | -57.91642M |
| Other liab | - | 0.00188M | 0.00004M | 0.04M | 0.02M |
| Good will | - | - | - | - | - |
| Other assets | - | 1.22M | 0.96M | 1.27M | 1.72M |
| Cash | 11.66M | 17.16M | 22.11M | 25.05M | 3.25M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 2.70M | 2.22M | 1.50M | 1.12M | 0.52M |
| Current deferred revenue | - | 0.70M | 0.71M | 0.97M | 0.27M |
| Net debt | -11.65732M | -16.97067M | -21.93487M | -25.02678M | -3.23154M |
| Short term debt | - | 0.04M | 0.03M | 0.02M | 0.04M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | - | 0.19M | 0.18M | 0.02M | 0.02M |
| Other stockholder equity | - | 0.11M | 3.17M | 3.47M | 1.13M |
| Property plant equipment | - | 0.20M | 0.23M | 0.03M | 0.07M |
| Total current assets | 14.73M | 20.41M | 23.67M | 25.75M | 4.41M |
| Long term investments | - | 0.16M | - | - | - |
| Net tangible assets | - | 19.62M | 23.18M | 25.90M | 5.64M |
| Short term investments | - | 1.83M | 1.83M | - | - |
| Net receivables | 1.39M | 0.42M | 0.66M | 0.33M | 0.33M |
| Long term debt | - | - | - | - | - |
| Inventory | 1.58M | 0.84M | 0.33M | 0.29M | 0.80M |
| Accounts payable | 2.14M | 1.19M | 0.72M | 0.11M | 0.16M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 3.17M | 3.24M | 3.17M | 3.47M | 1.13M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | 62.43M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.67M | 1.22M | 0.96M | 1.27M | 1.72M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 0.82M | 1.58M | 1.18M | 1.30M | 1.79M |
| Capital lease obligations | - | 0.19M | 0.21M | 0.02M | 0.06M |
| Long term debt total | - | 0.00000M | 0.00000M | 0.00000M | 0.02M |
| Breakdown | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
| Investments | 0.33M | -2.62128M | 0.01M | 0.00257M | -0.00086M |
| Change to liabilities | - | 0.69M | 0.29M | 0.59M | -0.36244M |
| Total cashflows from investing activities | - | -2.62128M | 0.01M | 0.00257M | -0.00086M |
| Net borrowings | - | -0.03501M | -0.03626M | -0.04061M | -0.40804M |
| Total cash from financing activities | 0.00083M | -0.03501M | -0.03626M | 26.49M | 1.17M |
| Change to operating activities | - | 1.26M | -0.49414M | -0.04507M | 0.02M |
| Net income | -6.93696M | -3.78651M | -2.85425M | -8.38447M | -2.92721M |
| Change in cash | -5.50245M | -4.95051M | -2.93700M | 21.80M | -1.86942M |
| Begin period cash flow | 17.16M | 22.11M | 25.05M | 3.25M | 5.12M |
| End period cash flow | 11.66M | 17.16M | 22.11M | 25.05M | 3.25M |
| Total cash from operating activities | -5.55996M | -2.48852M | -3.13219M | -4.08330M | -3.16477M |
| Issuance of capital stock | 0.02M | 0.00000M | 0.00000M | 29.28M | 1.96M |
| Depreciation | 0.05M | 0.05M | 0.03M | 0.04M | 0.04M |
| Other cashflows from investing activities | 0.33M | -2.61354M | 0.02M | 0.00920M | 0.00920M |
| Dividends paid | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Change to inventory | -0.19428M | -0.77610M | 0.28M | 0.96M | -0.11363M |
| Change to account receivables | -0.95847M | 0.23M | -0.33700M | 0.02M | 0.64M |
| Sale purchase of stock | - | 0.00000M | 0.00000M | 29.28M | 1.96M |
| Other cashflows from financing activities | -0.00758M | -0.04467M | -0.04245M | -2.76063M | -0.43356M |
| Change to netincome | - | -0.25625M | -0.05023M | 2.74M | -0.44544M |
| Capital expenditures | 0.00019M | 0.00774M | 0.01M | 0.00663M | 0.00086M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -0.97481M | 1.40M | -0.26992M | 1.53M | 0.18M |
| Stock based compensation | 0.00330M | 0.23M | 0.09M | 2.12M | -0.53391M |
| Other non cash items | 1.33M | 0.47M | -0.20563M | 1.25M | -0.53993M |
| Free cash flow | -5.56015M | -2.49626M | -3.14224M | -4.08993M | -3.16563M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (AUD) | Price (AUD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| IMC Immuron Ltd |
- -% | 0.07 | - | - | 2.42 | 1.53 | 0.66 | 1.15 |
| CSL CSL Ltd |
-3.26 1.35% | 238.71 | 28.85 | 33.67 | 7.67 | 4.14 | 5.94 | 18.44 |
| TLX Telix Pharmaceuticals Ltd |
-0.75 2.91% | 25.00 | 183.21 | 21.01 | 10.96 | 15.11 | 10.80 | 91.38 |
| MSB Mesoblast Ltd |
-0.12 6.70% | 1.67 | - | 454.55 | 414.37 | 3.34 | 67.90 | -9.8623 |
| NEU Neuren Pharmaceuticals Ltd |
-0.48 3.72% | 12.44 | 13.00 | 81.97 | 8.10 | 4.86 | 7.25 | 8.80 |
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops Travelan (IMM-124E), which is in Phase II clinical trial, to reduce the risk of contracting travelers' diarrhea; and IMM-529, which is in Phase II clinical trial, for treating patients suffering from recurring clostridium difficile infection. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
62 Lygon Street, Carlton, VIC, Australia, 3053
| Name | Title | Year Born |
|---|---|---|
| Mr. Steven George Lydeamore CPA, CPA, M.B.A., MBA | Chief Exec. Officer | 1968 |
| Dr. Jerry Kanellos Ph.D. | Chief Operating Officer | 1961 |
| Mr. Phillip Allen Hains BBus(Acc), CA, MBA | CFO & Company Sec. | 1959 |
| Mr. David Lyon | Head of Marketing | NA |
| Dr. Dan Ruben Peres | Chief Medical Officer | 1976 |
| Mr. Flavio Palumbo | Chief Commercial Officer | NA |
| Mr. Steven George Lydeamore CPA, M.B.A. | Chief Executive Officer | 1968 |
| Mr. Flavio Palumbo | Chief Commercial Officer | 1974 |
| Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A. | CFO & Company Secretary | 1959 |
| Mr. Steven George Lydeamore CPA, M.B.A. | Chief Executive Officer | 1968 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...